Electronic Supplementary Material (ESI) for RSC Advances.
This journal is © The Royal Society of Chemistry 2016
Supporting Information
1,8-di(piperidinyl)-naphthalene – Rationally Designed MAILD/MALDI Matrix for
Metabolomics and Imaging Mass Spectrometry
Jerrit Weißflog, Aleš Svatoš*
Mass Spectrometry/Proteomics Research Group Max Planck Institute for Chemical Ecology
Hans-Knoell-Strasse 8, 07745 Jena (Germany)
*Corresponding Author: Dr. Aleš Svatoš
Tel.:
+49 (0) 3641 57 1700
E-mail: [email protected]
Table of Contents
Figure S 1. Mass spectrum of palmitic acid recorded with various matrices…………..............S-2
Figure S 2. Mass spectrum of pure DPN recorded in positive and negative ion mode….…..…S-2
Figure S 3. Mass spectra of a mixture of palmitic, stearic and arachidic
acid and oleic acid recorded using 9-aminoachridine as matrix.................………………..…...S-3
Figure S 4. TOF-response curve of stearic acid recorded with DPN..........………………..….S-3
Figure S 5. Mass spectrum of Glucose recorded using DPN as matrix…………..…….…..….S-4
Figure S 6. UV-Vis spectra of pure DPN and DPN co-crystallized with
acetic acid recorded in solid state ……………………......................................................….….S-4
Figure S 7. AP-MALDI-FTMS-spectra of PE36:1 and PC 34:1 with DPN as matrix….……...S-5
Figure S 8. ESI-FTMS-spectra of pure PC 34:1 and as mixture with DPN ….................….….S-5
Table S 1. Assignments of peaks of the mass spectra recorded via AP-MALDI-FT-MS of
diluted fresh blood……………………………………………………………………………....S-7
S-1
N
N
N
HN
N
N
N
NH
N
N
N
N
Figure S 1. Mass spectrum of palmitic acid ([M-H]-, m/z 255) when recorded with various
matrices in 1:1 molar ratio (top left: TMGN, 175 pmol; top right: compound 4, 500pmol; bottom
left: compound 6, 500pmol; bottom right: compound 7, 125 pmol) (MALDI-TOF MS, neg. ion
mode)
15062016pureDPN 16 (0.402)
TOF LD+
670
294.2
%
100
292.2
295.2
1nmol
0 DPN LDI
100
200
300
15062016pureDPN_neg
22
(0.550) 400
500
600
700
800
900
m/z
1000
TOF
LD150
500
600
700
800
900
m/z
1000
%
100
0
100
200
300
400
S-2
Figure S 2. Mass spectrum (LDI-TOF MS) of pure DPN (1 nmol on plate) recorded in positive
(top) and negative (bottom) ion mode
9AA 500pmol + FA Mix 50pmol LE280
08062015 9AAC500+FAMix50LE280 1 (0.017)
TOF LD1.32e3
193.0
%
100
S/N = 8
194.0
255.2 311.3
0 + 9AAC
Oleic
150 200 250 2300
350
220812Oleic+AAC-1
(0.064)
450
500
550
600
650
700
m/z
750 TOF
800LD1.05e3
450
500
550
600
650
700
750
193.1
%
100
400
281.3
194.1
0
150
200
250
S/N = 16
300
350
400
m/z
800
Figure S 3. Mass spectra of a mixture of palmitic, stearic and arachidic acid (top, 50 pmol on
plate each) and oleic acid (bottom, 125 pmol) recorded using 9-aminoachridine as matrix
(MALDI-TOF MS, neg. ion mode)
S-3
100000
80000
60000
100
O
0
OH
11
%
Signal intensity (a.u.)
120000
260
270
280
290
300
310
320
m/z
R2=0.9982
40000
20000
0
0
50
100
150
200
250
300
Amount (pmol on plate)
Figure S 4. TOF-detector response curve for increasing concentrations of stearice acid recorded
with DPN as matrix. The inset shows a spectrum of stearic acid at 500fmol on plate (S/N=4).
500pmol DPN +500pmol Glucose
15062016DPN+Glucose_low_neg4 15 (0.375)
100
TOF LD534
179.063
-
%
[Glucose-H]
367.041
0
200
300
400
500
600
700
800
900
m/z
1000
Figure S 5. Mass spectrum of glucose (500 pmol on plate) recorded using DPN as matrix
(MALDI-TOF MS, neg. ion mode)
S-4
1
0.9
DPN pure
0.8
DPN/AcOH
absorbance
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
250
300
350
400
450
500
wavelength in nm
Figure S 6. UV-Vis spectra of pure DPN (red) and DPN cocrystallized with acetic acid
(1:1,blue) recorded in solid state
S-5
100
744.554
Relative Abundance
90
O
80
O
O
70
O
PE 36:1
60
O
O
P
O
O
50
40
30
20
10
0
500
550
600
650
700
100
750
m/z
800
850
900
950
699.496
Relative Abundance
90
744.554
80
O
70
O
687.496
60
O
O
50
O
O
P
O
N
O
PC 34:1
673.481
40
30
794.547
20
10
0
500
550
600
650
700
750
m/z
800
850
900
950
Figure S 7. AP-MALDI-FTMS spectra of PE 36:1 (top) and PC 34:1 (bottom) recorded with
DPN as matrix (not normalized, negative ion mode)
S-6
NH2
100
O
90
Relative Abundance
794.548
O
O
O
O
80
O
P
O
N
O
PC 34:1
70
744.554
Electrospray neg. ion mode
60
50
40
30
20
10
0
500
550
600
100
650
700
800
850
900
950
O
699.496
O
758.569
90
Relative Abundance
750
m/z
O
O
O
80
O
P
O
N
O
PC 34:1
70
60
744.553
50
N
818.591
N
673.480
40
DPN
30
794.547
20
10
0
500
550
600
650
700
750
m/z
800
850
900
950
Figure S 8. ESI-FTMS spectra of pure PC 34:1 (0.1 mol/ml in MeOH, top) and PC 34:1 mixed
with DPN (1:1(v/v), 500 pmol/ml in MeOH, bottom) (not normalized, negative ion mode)
S-7
detected
m/z
105.01
8
111.01
9
115.03
9
116.07
1
118.05
0
121.02
8
128.03
4
130.05
0
130.08
6
131.04
5
131.08
1
132.02
9
135.03
0
136.03
9
137.02
3
138.05
5
145.06
1
146.04
5
154.06
1
160.04
0
167.06
1
168.04
2
171.04
0
171.07
7
178.05
0
Assignment
C3H5O 4
C4H3O 2N2
C5H7O 3
C5H10O2N
C4H8O 3N
C7H5O 2
C5H6O 3N
C5H9O 3N
C6H12O2N
C4H7O 3N2
C5H11O2N2
C4H6O 4N
C5H7O 5
C7H6O 2N
C7H5O 3
C5H9O2NNa
C5H9O 3N2
C5H8O 4N
C6H8O 2N3
C9H8O 2N
C5H12O2N2
Cl
C4H11O4NP
C6H7O 4N2
C7H11O3N2
C9H8O 3N
C6H11O6
C9H10O3N
C5H12O4NS
C8H13O3N2
C7H11O4N2
C5H10O4N2
Cl
C8H13O4N2
C5H10O7P
C6H12O6Cl
C9H13O4N3
C10H15O4N2
C11H19O3N2
C14H27O2
C10H16O4N3
C9H18O4N2
Cl
C16H29O2
C16H31O2
C8H19O6NP
C14H17O3N2
C10H13O5N4
C17H33O2
C12H20O4N3
C12H16O3N2
Cl
C15H14O4N
C11H18O5N3
C10H15O6N3
C9H18O3N5S
C10H14O5N2
C10H17O4N3
Cl
C11H21O3N3
Cl
C18H31O2
C10H19O4N3
Cl
C18H33O2
C18H35O2
C13H22O4N3
as
Glyceric acid
Uracile
3/5-keto valeric acid
Valine
Threonine
Benzoic acid
Pyroglutamic acid
Hydroxyproline
Leucine/Isoleucine
Asparagine
Ornithine
Aspartic acid
Threonic/erythronic acid
Anthranilic acid
2/3/4-Hydroxy benzoic
acid
Valine
Glutamine
Dipeptide[Ala+Gly]
Glutamic acid
Histidine
3-Indole carboxylic acid
Ornithine
Phosphocholine
Hydantoin-5-propionic
acid
Dipeptide[Pro+Gly]
Hippuric acid
Glucose
Tyrosine
Choline sulfate
Dipeptide[Pro+Ala]
Dipeptide[Hyp+Gly]
Dipeptide[Gly+Ser]
Dipeptide[Pro+Ser]
Dipeptide[Hyp+Ala]
Deoxyribosephosphates
Glucose
Deoxycytidine
Dipeptide[Pro+Hyp]
Dipeptide[Leu/Ile+Pro]
Myristic acid
Dipeptide[Gln+Pro]
Tripeptide[Gly+Pro+Ala]
Dipeptide[Val+Thr]
FA (16:1)
Palmitic acid
Glycerophosphocholine
Dipeptide[Pro+Phe]
Dipeptide[His+Asp]
Heptadecanoic acid
Tripeptide[Gly+Pro+Val]
Dipeptide[Phe+Ala]
Thyronine
Tripeptide[Gly+Pro+Thr]
Tripeptide[Ala+Pro+Ser]
Dipeptide[Gln+Glu]
Dipeptide[Arg+Cys]
Dipeptide[Pro+Glu]
Dipeptide[Gln+Pro]
Tripeptide[Gly+Pro+Ala]
Dipeptide[Lys+Pro]
FA (18:2)
Dipeptide[Gln+Val]
Dipeptide[Leu/Ile+Asn]
Tripeptide[2xGly+Ile/Leu]
Tripeptide[Gly+Val+Ala]
FA (18:1)
Stearic acid
Tripeptide[Pro+Gly+Ile]
Tripeptide[Pro+Gly+Leu]
Tripeptide[Pro+Val+Ala]
Deoxyadenosine
Tripeptide[Pro+Thr+Ala]
Tripeptide[Pro+2xAla]
Phosphopantothenic acid
Tripeptide[2xPro+Ser]
[M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M2H+Na][M-H][M-H][M-H][M-H][M+Cl][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M+Cl][M-H][M-H][M+Cl][M-H][M-H][M-H][M-H][M-H][M+Cl][M-H][M-H][M-H][M-H][M-H][M-H][M-H][M+Cl][M-H][M-H][M-H][M-H][M-H][M+Cl][M+Cl][M-H][M+Cl]-
[M-H][M-H][M-H][M+Cl][M-H][M+Cl][M-H][M-H][M-H]-
detected by
DMAN
DPN
+
+
+
+
++
+
+
+
+
+
++
++
+
+
+
+
+
+++
+
+
+
+
+
+
++
+
++
+
++
+++
++
++
+
-
+++
+
+
+++
+
+
+
+
+
+
++
+
+
+
+
+
++++
+
-
+
++++
+
+
+
+
+
+
+
++
-
+
+
++
+++
++
+
+
+
++
+
-
+
+
+
+
+
-
+
++
+
+
+
-
++
++
+
+
+
-
+
+
+
+
+
+
S-8
Table S 1: Assignments of peaks of the mass
spectra recorded via AP-MALDI-FT-MS of
diluted fresh blood. The peaks were assigned
via their accurate mass with <5 ppm mass
accuracy (<10 ppm below 200 m/z) and their
isotopic pattern. Peaks of an intensity below
100 a.u. were ignored. (PA: phosphatidic
acid, PE: phosphatidylethanolamine, PI:
phosphatidylinositol, PS: phosphatidylserine,
PG:
phosphatidylglycerol,
PC:
phosphatidylcholine, SM: sphingomyelin,
Cer: cerebroside, CerP: ceramide phosphate,
PE-Cer:
ceramide
Metabolites
with
phosphoethanolamine).
*
confirmed via MS/MS.
were
additionally
179.05
5
180.06
6
182.04
8
C10H13O3N5
ClC12H20O5
N3
C11H19O4N3
Cl
C9H17O8NP
C13H20O5N3
C14H24O4N3
Tripeptide[Ala+Leu/Ile+Pr
o]
185.09
2
187.07
2
197.03
5
201.08
8
213.01
7
215.03
2
226.08
3
227.10
4
227.14
0
227.20
1
242.11
5
253.09
8
253.21
8
255.23
3
256.09
8
261.12
5
269.08
8
269.24
9
270.14
6
271.08
5
272.09
3
272.12
6
273.09
7
276.11
S-9
2
278.06
7
278.09
2
278.12
8
279.23
3
280.10
7
281.24
9
283.26
5
284.16
2
286.07
2
286.14
1
292.10
7
298.07
0
298.14
1
298.17
8
detected
m/z
Assignment
as
detected by
DMAN
DPN
S-10
Table S 1 contd.
299.13
7
C12H19O5N4
C20H31O2
C10H15O4N5
Cl
303.23
3
C10H16O6N3
S
304.08
3
306.07
7
306.12
3
308.13
9
312.15
7
320.13
9
322.11
8
327.13
6
334.15
4
C12H21O4N3
ClC12H23O4
N3Cl
C14H22O5N3
C13H22O4N3
Cl
C12H20O5N3
ClC18H19O4
N2
C14H24O4N3
Cl
C12H23O5N4
S
C13H24O4N4
ClC12H23O4
N6S
C13H22O5N4
Cl
C14H24O5N4
Cl
C16H26O6N5
C19H36O6P
C15H24O5N6
Cl
335.14
1
335.15
0
347.14
9
349.12
9
C27H43O3
C21H38O6P
C21H40O6P
C27H43O4
C27H45O4
C21H42O7P
C19H35O5N5
Cl
363.14
5
384.18
9
C27H45O4S
C27H46O4Cl
C19H37O6N8
C22H31O6N4
S
391.22
6
403.15
1
C21H42O7P
C22H34O6N4
S
415.32
2
417.24
2
419.25
C22H31O7N4
S
Tripeptide[Asn+Pro+Ala]
Tripeptide[Gln+Pro+Glu]
Tetrapeptide[2xGly+Pro
+Ala]
Arachidonic acid
Dipeptide[Asn+His]
Tripeptide[2xGly+His]]
Tripeptide[Asn+Cys+Ala]
Tripeptide[Gly+Cys+Glu]
Glutathione
Tripeptide[Gly+Pro+Val]
Tripeptide[2xAla+Leu]
Tripeptide[2xAla+Ile]
Tripeptide[2xVal+Gly]
Tripeptide[2xPro+Thr]
Tripeptide[Pro+Gly+Ile]
Tripeptide[Pro+Gly+Leu]
Tripeptide[Pro+Val+Ala]
Tripeptide[Pro+Thr+Ala]
Dipeptide[Phe+Tyr]
Tripeptide[Ala+Leu+Pro]
Tripeptide[Ala+Ile+Pro]
Tripeptide[Ser+Lys+Cys]
Tripeptide[Pro+Lys+Gly]
Tripeptide[Ala+Cys+Arg]
Tripeptide[Gln+Pro+Ala]
Tetrapeptide[2xAla+Pro
+Gly]
Tripeptide[Val+Pro+Asn]
Tetrapeptide[2xGly+Pro
+Val]
Tetrapeptide[2xAla+Pro+
Gln]
Tetrapeptide[Asn+Gly+
Pro +Val]
cPA (16:0/0:0)
Tripeptide[Val+His+Asn]
Tetrapeptide[2xGly+His
+Val]
Tetrapeptide[3xAla+His]
Cholestenoic acid
Dihydroxyvitamin D3
cPA (18:1/0:0)
cPA (18:0/0:0)
Dihydroxycholestenoic
acid
Trihydroxyvitamin D3
Dihydroxycholestanoic
acid
Dihydroxyprostanic acid
LysoPA18:0/0:0
Tetrapeptide[Lys+Gly+Pr
o+Ile]
Tetrapeptide[Lys+Gly+Pr
o+Leu
Tetrapeptide[Lys+Ala+Pr
o+Val]
Cholesterol sulfate
Dihydroxycholestanoic
acid
Tetrapeptide[Lys+Ala+
Thr+Arg]
Tetrapeptide[Cys+Pro
+Val+Tyr]
Tetrapeptide[Tyr+Pro+
Ala+Met]
Tetrapeptide[Pro+Ser+
Met +Phe]
LysoPE (18:0/0:0)
Tetrapeptide[Met+Leu/Ile
+
Gly+Tyr]
Tetrapeptide[Val+Ser+
Phe+Met]
Tetrapeptide[Ala+Val+
Met +Tyr]
Tetrapeptide[2xVal+
Cys +Tyr]
Tetrapeptide[Cys+Leu/Ile
+
Asp+Phe]
Tetrapeptide[Tyr+Ser+Pr
[M-H]-
-
+
[M-H][M+Cl]-
-
+
+
[M-H]-
++
+
[M+Cl][M+Cl]-
-
+
+
[M+Cl][M+Cl]-
-
+
+
[M+Cl][M-H][M+Cl]-
-
+
+
+
[M-H][M+Cl][M-H][M+Cl]-
+
+
+
+
+
[M+Cl]-
-
+
[M-H]-
-
+
[M-H][M+Cl]-
-
+
+
[M-H]-
-
+
[M-H][M-H][M-H]-
-
+
++
+
[M-H]-
++
++
[M-H][M-H]-
+
+
-
[M-H][M+Cl][M-H]-
+
-
++
+
+
[M-H]-
-
+
[M-H][M-H]-
-
+
+
[M-H]-
-
+
S-11
7
o
+Met]
Tetrapeptide[Ala+Glu+M
et +Phe]
Tetrapeptide[Val+Phe+C
ys +Glu]
431.31
7
433.33
3
437.26
8
448.23
4
465.30
5
469.30
9
473.28
3
479.19
8
480.31
0
481.21
4
495.19
3
detected
m/z
Assignment
as
detected by
DMAN
DPN
S-12
Table S 1 contd.
497.20
9
C22H33O7N4S
C22H31O8N4S
511.18
8
C25H29O8N4S
C23H35O6N8
513.20
4
519.27
1
C19H36O7N11
C24H38O5N9
C26H48O9P
C26H42O5N5S
C27H40O5N5S
530.28
2
532.29
7
C24H48O9PCl
C26H38O6N5S
C22H38O6N9Na
C26H46O7NPCl
C22H41O6N9Na
535.30
5
536.29
2
546.27
7
547.28
4
548.25
6
548.29
3
550.27
2
C26H42O6N5S
C23H38O11N5
C27H41O5N6
C24H36O7N9
C28H52O9P
C27H48O7NPCl
C27H50O7NPCl
C28H39O5N8
C31H38O5N6
C27H38O7N5S
C31H41O6N6
C24H36O8N9
C22H38O8N9Na
550.30
8
C26H46O9NPCl
C27H50O8NPCl
C32H63O6NP
C30H57NO8P
C32H43O5N6
552.28
7
C30H56O9P
C24H36O9N9
560.25
6
561.28
7
C24H40O9N9
Tetrapeptide[Cys+Leu/Ile [M-H]+Thr
+Tyr]
Tetrapeptide[Tyr+Ser+Va
l
+Met]
[M-H]Tetrapeptide[2xThr+Met+
Phe]Tetrapeptide[Cys+Le
u/Ile+Tyr
+Asp]
Tetrapeptide[Tyr+Ala+Gl
u
+Met]
Tetrapeptide[Ser+Glu+ [M-H]Met +Phe]
[M-H]Tetrapeptide[Met+Phe+
Asp+Thr]
Tetrapeptide[Met+Tyr+
[M-H]2xThr]
Tetrapeptide[Ser+Lys+
Met +Arg]
[M-H]Tetrapeptide[Leu/Ile+Pro
[M-H]+
Gln+Lys]
[M-H]Tetrapeptide[2xArg+Asn+
Ser]
[M-H]Tetrapeptide[2xHis+Lys+
Leu/Ile]
[M+Cl]LysoPG (20:2/0:0)
[M-H]Tetrapeptide[Met+Phe+
Lys+Leu/Ile]
[MTetrapeptide[Met+Val+ 2H+Na]Trp+Leu/Ile]
LysoPG (18:0/0:0)
[M+Cl]Tetrapeptide[Met+Thr+ [M2H+Na]Trp+Leu/Ile]
Tetrapeptide[Lys+Arg+
Glu+Pro]
LysoPC (18:4/0:0)
Tetrapeptide[Arg+Asn+
[M-H]Lys+Leu/Ile]
Tetrapeptide[Arg+Gln+ [M-H]Lys+Val]
Tetrapeptide[Met+Tyr+ [M-H]Lys+Leu/Ile]
Pentapeptide[Ser+Asp+ [M-H]Glu+Val+Leu/Ile]
Tetrapeptide[Met+Trp+ [M-H]Lys+Val]
[M+Cl]Tetrapeptide[Arg+Asn+ [M+Cl]Gln+Phe]
[M-H]LysoPG (22:2/0:0)
LysoPE (22:4/0:0)
[M-H]LysoPE (22:3/0:0)
Tetrapeptide[His+Val+
[M-H]Lys+Trp]
Tetrapeptide[2xTrp+Ala+ [M-H]Leu/Ile]
Tetrapeptide[Trp+Met+ [M-H]Glu+Leu/Ile]
Tetrapeptide[Trp+Phe+ [MVal+Lys]
2H+Na]Tetrapeptide[Arg+Asn+
Tyr+Gln]
[M+Cl]Tetrapeptide[Arg+Lys+ [M+Cl]Glu+Gln]
[M-H]LysoPS(20:3/0:0)
[M-H]LysoPE (OH-22:3/0:0)
[M-H]CerP(d18:1/14:0)
fragment of PE(22:/16:0) [M-H]Tetrapeptide[Leu/Ile+Lys [M-H]+Trp
+Phe]
[M-H]LysoPG (24:2/0:0)
Pentapeptide[His+Pro+
Ser+2xGln]
Pentapeptide[Glu+Pro+
Lys+2xAsn]
-
+
-
+
++
+
+
-
+
-
++
-
+
+
-
+
-
+
+
-
++
-
+
++
-
+
-
+
-
+
-
++
-
++
++
+
+
-
+
-
+
-
+
-
+
-
++
-
+
+
+
++
+
+
-
++
+
-
+
562.27
2
S-13
563.33
6
564.28
8
566.30
3
567.30
7
573.28
2
576.25
1
577.31
6
578.26
7
580.28
3
582.26
1
582.29
8
588.44
1
589.35
2
591.33
2
591.36
8
594.26
2
598.29
3
detected
m/z
Assignment
as
detected by
DMAN
DPN
S-14
Table S 1 contd.
599.32
2
601.31
3
605.35
2
606.34
2
615.17
1
616.47
2
622.33
7
627.32
9
630.48
8
631.16
6
637.15
3
642.48
8
644.50
4
647.16
1
648.16
9
650.14
0
650.40
5
651.14
7
C27H52O12P
C33H41O5N6
C31H61NO8P
C32H44O5N7
C34H31O4N4Fe
C34H67O6NP
C33H44O6N7
C30H43O7N8
C35H69O6NP
C34H31O5N4Fe
C34H30O4N4Fe
Na
C36H69O6NP
C36H71O6NP
C34H31O6N4Fe
C34H32O6N4Fe
C34H31O4N4Fe
Cl
C32H61O10NP
C34H32O4N4Fe
Cl
C28H47O8N10
C35H66O8NP
C36H72O6N2P
C33H61O10NP
C34H65O9NP
C33H63O10NP
C37H68O8P
C37H70O8P
C38H76O6N2P
C39H68O8P
C39H70O8P
C39H72O8P
C39H74O8P
C40H80O6N2P
C39H77O8NP
C41H70O8P
C41H72O8P
C41H74O8P
C42H81O6NP
C41H77O8NP
C41H79O8NP
C43H72O8P
C43H74O8P
C43H77O8NP
C43H81O8NP
C44H88O6N2P
C46H90O6N2P
C46H92O6N2P
C44H47O10NP
C47H82O13P
LysoPI (18:0/0:0)
[M-H]Tetrapeptide[Leu/Ile+Val [M-H]+
2xTrp]
[M-H]fragment of PE(22:/16:0) [M-H]Tetrapeptide[2xLys+Phe [M-H]+Trp]
[M-H]Heme B (ferrous)*
[M-H]CerP(d18:1/16:0)
[M-H]Tetrapeptide[2xLys+Tyr+ [M-H][M-H]Trp]
Tetrapeptide[2xTyr+Lys+ [MArg]
2H+Na]CerP(d18:1/17:0)
[M-H]Heme B (Oxo-complex)*
Heme B (ferrous)
[M-H]CerP(d18:2/18:0)
[M-H]CerP(d18:1/18:1)
[M-H]CerP(d18:1/18:0)
[M-H]Heme B (oxy)
[M-H]Heme B (hydroperoxo)* [M+Cl]Hemin B
[M-H]PS (26:0)
Heme B (ferrous)
[M-H]Pentapeptide[Glu+Ile/Leu [M-H][M-H]+Arg+His+Val]
PE (30:2)
[M-H]PE-Cer(34:1)
[M-H]PS (27:1)
[M-H]PS (P-16:0/12:0)
[M-H]PS (27:0)
[M-H]PA(34:2)
[M-H]PA(34:1)
[M-H]PE-Cer (36:1)
[M-H]PA (36:4)
[M-H]PA (36:3)
[M-H]PA (36:2)
[M-H]PA (36:1)
[M-H]PE-Cer(38:1)
[M-H]PE (34:0)
[M-H]PA(38:5)
[M-H]PA(20:4/18:1)*
[M-H]PA(38:3)
[M-H]CerP(d18:1/24:1)
[M-H]PE (36:2)
[M-H]PE (36:1)
[M-H]PA(40:6)
[M-H]PA(40:5)
PE (20:4/18:0)*
PE (20:2/18:0)*
[M-H]PE (20:1/18:1)*
[M-H]PE (20:0/18:2)*
[M-H]PE-Cer (42:1)
[M-H]PE-Cer (44:2)
[M-Na]PE-Cer (44:1)
PS (38:4)
PI (20:4/18:0)*
+
-
+
+
+
+++
+
++
+
++
+
+++
++
+
+
++
+++
++
+++
+
++
++
++
++
-
+
++
++
+
++
+
+
+
+
+
-
+
+
+
+
+
+
+
+++
+
+
++
+
+
+
+
++
+
+
++
+
+
+
+
+
-
+
+
+
+
++
651.35
6
658.44
8
659.51
5
662.40
5
662.44
2
664.42
1
671.46
7
673.48
2
S-15
687.54
6
695.46
6
697.48
3
699.49
8
701.51
4
715.57
7
718.54
0
721.48
3
723.49
9
725.58
6
726.58
2
742.54
1
744.55
6
747.49
9
749.51
4
766.54
0
770.57
2
771.64
0
797.65
6
799.67
1
810.53
0
885.55
2
S-16